8-K: Aptose Biosciences Secures $25 Million Equity Line and Establishes At-The-Market Facility

Aptose Biosciences has entered into a common share purchase agreement for a $25 million committed equity facility and established a new at-the-market (ATM) facility.

Summary

• Aptose Biosciences Inc. has entered into a common share purchase agreement with an institutional investor for a committed equity facility.
• The agreement allows Aptose, at its discretion, to sell up to $25 million of its common shares over 24 months, subject to certain conditions and limitations.
• The securities offered have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
• No Common Shares will be sold on the Toronto Stock Exchange (TSX) or other trading market in Canada under the common share purchase agreement.
• The TSX has conditionally approved the committed equity facility based on the exemption set forth in Section 602.1 of the TSX Company Manual.
• Aptose has also entered into a sales agreement for at-the-market (ATM) distributions on the Nasdaq.
• Aptose will decide the timing, price, and number of shares sold under the ATM facility.
• Prospectus supplements have been filed with the SEC for the offer and sale of common shares (i) to the Investor with an aggregate offering price of up to US $25 million and (ii) pursuant to the sales agreement with an aggregate offering price of up to US $1 million.

Sentiment

Score: 6

Explanation: The announcement is neutral. While securing funding is positive, the reliance on equity financing can be viewed as dilutive to existing shareholders. The company's future success depends on its clinical trials and ability to bring its products to market.

Positives

• The $25 million committed equity facility provides Aptose with financial flexibility.
• The at-the-market facility offers an additional avenue for raising capital.

Risks

• The securities offered have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
• The company's ability to obtain the capital required for research and operations and to continue as a going concern is a risk.
• The inherent risks in early stage drug development including demonstrating efficacy is a risk.
• Development time/cost and the regulatory approval process is a risk.
• The progress of the company's clinical trials is a risk.
• The company's ability to find and enter into agreements with potential partners is a risk.
• The company's ability to attract and retain key personnel is a risk.
• Changing market conditions is a risk.
• Inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities is a risk.
• Unexpected manufacturing defects is a risk.

Future Outlook

The company expects that any net proceeds received by the Company from such sales to the Investor will be used for working capital and general corporate purposes.

Management Comments

• Management of the Company believes that it is in the Company's best interests to have the flexibility to sell Common Shares pursuant to the Purchase Agreement, subject to market conditions.

Industry Context

This announcement reflects a common financing strategy for clinical-stage biotechnology companies to secure funding for ongoing research and development activities.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company's employees and partners benefit from the increased financial stability.

Next Steps

• Aptose will file necessary documents with the SEC to register the shares for resale.
• Aptose will decide on the timing and amount of shares to sell under the equity facility and ATM program based on market conditions and funding needs.

Key Dates